



Tarsus to Participate in Upcoming Investor Conferences

May 7, 2026

IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

- Bank of America Securities 2026 Health Care Conference on Tuesday, May 12th, at 3:40 p.m. PT / 6:40 p.m. ET.
- H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19th, at 8:00 a.m. PT / 11:00 a.m. ET.
- Stifel 2026 Virtual Ophthalmology Forum on Tuesday, May 26th, at 12:30 p.m. PT / 3:30 p.m. ET.

Live webcasts and additional information can be accessed on the events section of the Tarsus [website](#). Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEM[®] (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of *Demodex* blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2.

Media Contact:

Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:

David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com